Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ultragenyx’s Evkeeza Gets Label Update to Allow Use under Age 5
May 17, 2024
- No Clenafin Generic Competition until June 2025: Kaken
May 17, 2024
- Japan Generic Market Set to Surpass 1.6 Trillion Yen by 2032: Fuji Keizai
May 17, 2024
- Xocova Forerunner in March GP Rep Promotion Rankings: Intage
May 17, 2024
- Eisai Begins Rolling Submission for Subcutaneous Leqembi in US
May 16, 2024
- Eisai Sees Global Sales of Leqembi Surging to 56.5 Billion Yen in FY2024
May 16, 2024
- Mounjaro Going Back to Normal Supply from June: Lilly/Mitsubishi
May 16, 2024
- Amgen Files BiTE Drug Tarlatamab for Lung Cancer in Japan
May 16, 2024
- As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
- Teva to Let Go of Japan Generic Business in 2025 but Denies Full Exit
May 15, 2024
- Sanofi Files Sarclisa as 1st-Line Quad Therapy for MM in Japan
May 15, 2024
- Seikagaku’s Herniated Disk Drug Accepted for US FDA Review
May 15, 2024
- Sumitomo Pharma to Kick Off PI Study for Universal Flu Vaccine in Europe
May 15, 2024
- Sumitomo Seeks Label Expansion for Gemtesa in US
May 15, 2024
- Takeda, AC Immune Sign US$2 Billion Alzheimer’s Deal
May 14, 2024
- Sumitomo Pharma Replaces CEO amid Dismal Earnings
May 14, 2024
- Shionogi’s COVID-19 Pill Fails to Show Significant Difference in Global PIII
May 14, 2024
- Blackstone to Take I’rom Group Private in Bid to Address Japan’s Drug Lag
May 14, 2024
- Suzuken Eyes One-Stop Platform for Japan Launch of “Loss” Products
May 14, 2024
- Fycompa Approved for Label Expansion in China: Eisai
May 14, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…